Brokerages forecast that Arch Therapeutics Inc (NASDAQ:ARTH) will announce earnings of ($0.01) per share for the current quarter, according to Zacks. Zero analysts have issued estimates for Arch Therapeutics’ earnings, with estimates ranging from ($0.02) to ($0.01). Arch Therapeutics also posted earnings per share of ($0.01) in the same quarter last year. The company is expected to announce its next quarterly earnings report on Monday, December 4th.

On average, analysts expect that Arch Therapeutics will report full year earnings of ($0.05) per share for the current fiscal year, with EPS estimates ranging from ($0.06) to ($0.04). For the next year, analysts expect that the firm will report earnings of ($0.03) per share, with EPS estimates ranging from ($0.05) to $0.00. Zacks’ EPS calculations are a mean average based on a survey of analysts that that provide coverage for Arch Therapeutics.

A number of equities analysts have commented on ARTH shares. HC Wainwright set a $3.00 price objective on Arch Therapeutics and gave the stock a “buy” rating in a research note on Thursday, July 27th. Zacks Investment Research upgraded Arch Therapeutics from a “hold” rating to a “buy” rating and set a $0.75 price objective on the stock in a research note on Tuesday, October 17th. ValuEngine upgraded Arch Therapeutics from a “sell” rating to a “hold” rating in a research note on Saturday, August 26th. Finally, Ifs Securities restated an “outperform” rating on shares of Arch Therapeutics in a research note on Tuesday, July 25th. One analyst has rated the stock with a sell rating, one has issued a hold rating and four have issued a buy rating to the stock. Arch Therapeutics currently has a consensus rating of “Buy” and a consensus target price of $2.31.

WARNING: “Analysts Expect Arch Therapeutics Inc (ARTH) Will Post Earnings of -$0.01 Per Share” was reported by American Banking News and is the property of of American Banking News. If you are accessing this piece on another site, it was stolen and republished in violation of United States and international copyright law. The legal version of this piece can be accessed at https://www.americanbankingnews.com/2017/10/25/analysts-expect-arch-therapeutics-inc-arth-will-post-earnings-of-0-01-per-share.html.

Shares of Arch Therapeutics (NASDAQ:ARTH) opened at 0.7845 on Wednesday. Arch Therapeutics has a 52 week low of $0.41 and a 52 week high of $0.89. The company has a 50-day moving average price of $0.79 and a 200 day moving average price of $0.64. The firm’s market cap is $115.34 million.

Arch Therapeutics Company Profile

Arch Therapeutics, Inc is a development-stage company. The Company operates as a biotechnology company. The Company focuses on developing products to stop bleeding (hemostasis) and control leaking (sealant) during surgery and trauma care. The Company’s technology is based on a self-assembling peptide that creates a physical, mechanical barrier, which could be applied to seal organs or wounds that are leaking blood and other fluids.

Get a free copy of the Zacks research report on Arch Therapeutics (ARTH)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Arch Therapeutics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Arch Therapeutics Inc and related companies with MarketBeat.com's FREE daily email newsletter.